Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21170668rdf:typepubmed:Citationlld:pubmed
pubmed-article:21170668lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C0872097lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C1513178lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C1513095lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C0021701lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:21170668lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:21170668pubmed:issue4lld:pubmed
pubmed-article:21170668pubmed:dateCreated2011-5-31lld:pubmed
pubmed-article:21170668pubmed:abstractTextIntegrin ?v?3 plays a critical role in the survival and metastasis process of cancer cells. It is therefore desirable to develop new types of small molecule inhibitors of integrin ?v?3. IH1062 (3, 5-dichloro-phenylbiguanide) is a novel small molecule inhibitor of integrin ?v?3 that we have recently discovered. In this study, we investigated the induction effects of anoikis in human melanoma cell line M21 by IH1062, by detecting caspase activity, measuring the expression levels of apoptosis-related proteins, and performing the AnnexinV/PI apoptosis assay. Furthermore, we established a melanoma pulmonary metastasis mouse model in order to evaluate the suppression of metastasis by IH1062 in vivo. Our results demonstrate that IH1062 triggered human melanoma M21 cells to undergo anoikis by interrupting the attachment of M21 cells to extracellular matrix, reducing the phosphorylation of focal adhesion kinase, decreasing survivin and the ratio of Bcl-2/Bax proteins, and activating caspase cascades in vitro. Additionally, IH1062 showed markedly anti-metastatic effects in the pulmonary metastasis model in vivo, which makes it a promising lead to develop new drugs for anti-metastasis therapies.lld:pubmed
pubmed-article:21170668pubmed:languageenglld:pubmed
pubmed-article:21170668pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:citationSubsetIMlld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21170668pubmed:statusMEDLINElld:pubmed
pubmed-article:21170668pubmed:monthAuglld:pubmed
pubmed-article:21170668pubmed:issn1573-0646lld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:ZhouYuanYlld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:YangMingMlld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:XiongDongshen...lld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:PengHuiHlld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:FanDongmeiDlld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:YangChunzheng...lld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:RICOMMlld:pubmed
pubmed-article:21170668pubmed:authorpubmed-author:ZhangYongciYlld:pubmed
pubmed-article:21170668pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21170668pubmed:volume29lld:pubmed
pubmed-article:21170668pubmed:ownerNLMlld:pubmed
pubmed-article:21170668pubmed:authorsCompleteYlld:pubmed
pubmed-article:21170668pubmed:pagination666-73lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:meshHeadingpubmed-meshheading:21170668...lld:pubmed
pubmed-article:21170668pubmed:year2011lld:pubmed
pubmed-article:21170668pubmed:articleTitleAnoikis induction and metastasis suppression by a new integrin ?v?3 inhibitor in human melanoma cell line M21.lld:pubmed
pubmed-article:21170668pubmed:affiliationState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People's Republic of China.lld:pubmed
pubmed-article:21170668pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21170668pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed